LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study | Zendy

Xavier Bertagna | Zendy; Rosario Pivonello | Zendy; Maria Fleseriu | Zendy; Yiming Zhang | Zendy; Paul Robinson | Zendy; Ann E. Taylor | Zendy; Catherine E. Watson | Zendy; Mario Maldonado | Zendy; Amir H. Hamrahian | Zendy; Marco Boscaro | Zendy; Beverly M. K. Biller | Zendy

Open Access

LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study

Author(s) -

Xavier Bertagna,

Rosario Pivonello,

Maria Fleseriu,

Yiming Zhang,

Paul Robinson,

Ann E. Taylor,

Catherine E. Watson,

Mario Maldonado,

Amir H. Hamrahian,

Marco Boscaro,

Beverly M. K. Biller

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2013-2117

Subject(s) - medicine , discontinuation , cushing's disease , adverse effect , blood pressure , nausea , gastroenterology , clinical endpoint , adrenocorticotropic hormone , urinary system , endocrinology , hormone , disease , clinical trial

The clinical features and increased mortality associated with Cushing's syndrome result from a chronic excess of circulating cortisol. As LCI699 potently inhibits 11β-hydroxylase, which catalyzes the final step of cortisol synthesis, it is a potential new treatment for Cushing's disease, the most common cause of endogenous Cushing's syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research